多发性硬化症和波兰神经学会神经免疫学分会和波兰肿瘤学会免疫肿瘤学分会关于接受免疫调节治疗的多发性硬化症患者的肿瘤风险的建议。

IF 2.6 4区医学 Q2 CLINICAL NEUROLOGY

Neurologia i neurochirurgia polska Pub Date : 2025-01-01 Epub Date: 2025-01-15 DOI:10.5603/pjnns.101995

Iwona Rościszewska-Żukowska, Alina Kułakowska, Alicja Kalinowska, Halina Bartosik-Psujek, Dagmara Mirowska-Guzel, Mariusz Stasiołek, Beata Zakrzewska-Pniewska, Waldemar Brola, Sławomir Wawrzyniak, Marek Gołębiowski, Jacek Mackiewicz, Grażyna Kamińska-Winciorek, Anna M Czarnecka, Adam Maciejczyk, Sebastian Giebel, Piotr Rutkowski, Bożena Cybulska-Stopa, Monika Adamczyk-Sowa

{"title":"多发性硬化症和波兰神经学会神经免疫学分会和波兰肿瘤学会免疫肿瘤学分会关于接受免疫调节治疗的多发性硬化症患者的肿瘤风险的建议。","authors":"Iwona Rościszewska-Żukowska, Alina Kułakowska, Alicja Kalinowska, Halina Bartosik-Psujek, Dagmara Mirowska-Guzel, Mariusz Stasiołek, Beata Zakrzewska-Pniewska, Waldemar Brola, Sławomir Wawrzyniak, Marek Gołębiowski, Jacek Mackiewicz, Grażyna Kamińska-Winciorek, Anna M Czarnecka, Adam Maciejczyk, Sebastian Giebel, Piotr Rutkowski, Bożena Cybulska-Stopa, Monika Adamczyk-Sowa","doi":"10.5603/pjnns.101995","DOIUrl":null,"url":null,"abstract":"Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS) that is usually diagnosed between the ages of 20 and 40. Changes in the immune system also observed in cancer may suggest a higher prevalence of cancer in the MS patient population. In recent years, many highly effective immunosuppressive drugs have been introduced into disease-modifying therapy (DMT) which may be associated with a higher risk of cancer development in patients with MS. This paper presents current data on the oncological risk of individual drugs. In addition, it provides recommendations on the management for qualifying for DMT and monitoring the safety of the therapy from anoncological perspective.","PeriodicalId":19132,"journal":{"name":"Neurologia i neurochirurgia polska","volume":" ","pages":"20-32"},"PeriodicalIF":2.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society and Immuno-oncology Section of Polish Society of Oncology on oncological risk in patients with multiple sclerosis undergoing immunomodulatory therapy.\",\"authors\":\"Iwona Rościszewska-Żukowska, Alina Kułakowska, Alicja Kalinowska, Halina Bartosik-Psujek, Dagmara Mirowska-Guzel, Mariusz Stasiołek, Beata Zakrzewska-Pniewska, Waldemar Brola, Sławomir Wawrzyniak, Marek Gołębiowski, Jacek Mackiewicz, Grażyna Kamińska-Winciorek, Anna M Czarnecka, Adam Maciejczyk, Sebastian Giebel, Piotr Rutkowski, Bożena Cybulska-Stopa, Monika Adamczyk-Sowa\",\"doi\":\"10.5603/pjnns.101995\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS) that is usually diagnosed between the ages of 20 and 40. Changes in the immune system also observed in cancer may suggest a higher prevalence of cancer in the MS patient population. In recent years, many highly effective immunosuppressive drugs have been introduced into disease-modifying therapy (DMT) which may be associated with a higher risk of cancer development in patients with MS. This paper presents current data on the oncological risk of individual drugs. In addition, it provides recommendations on the management for qualifying for DMT and monitoring the safety of the therapy from anoncological perspective.\",\"PeriodicalId\":19132,\"journal\":{\"name\":\"Neurologia i neurochirurgia polska\",\"volume\":\" \",\"pages\":\"20-32\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurologia i neurochirurgia polska\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5603/pjnns.101995\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurologia i neurochirurgia polska","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5603/pjnns.101995","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

多发性硬化症（MS）是一种中枢神经系统（CNS）自身免疫性脱髓鞘疾病，通常在20至40岁之间被诊断出来。在癌症中也观察到免疫系统的变化，这可能表明多发性硬化症患者群体中癌症的患病率更高。近年来，许多高效的免疫抑制药物被引入到疾病修饰治疗（DMT）中，这可能与ms患者更高的癌症发展风险有关。本文介绍了目前有关单个药物肿瘤风险的数据。此外，它还提供了从肿瘤角度对DMT的管理资格和监测治疗安全性的建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society and Immuno-oncology Section of Polish Society of Oncology on oncological risk in patients with multiple sclerosis undergoing immunomodulatory therapy.

Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS) that is usually diagnosed between the ages of 20 and 40. Changes in the immune system also observed in cancer may suggest a higher prevalence of cancer in the MS patient population. In recent years, many highly effective immunosuppressive drugs have been introduced into disease-modifying therapy (DMT) which may be associated with a higher risk of cancer development in patients with MS. This paper presents current data on the oncological risk of individual drugs. In addition, it provides recommendations on the management for qualifying for DMT and monitoring the safety of the therapy from anoncological perspective.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Neurologia i neurochirurgia polska 医学-临床神经学

CiteScore

4.20

自引率

27.60%

发文量

128

审稿时长

6-12 weeks

期刊介绍： Polish Journal of Neurology and Neurosurgery is an official journal of the Polish Society of Neurology and the Polish Society of Neurosurgeons, aimed at publishing high quality articles within the field of clinical neurology and neurosurgery, as well as related subspecialties. For more than a century, the journal has been providing its authors and readers with the opportunity to report, discuss, and share the issues important for every-day practice and research advances in the fields related to neurology and neurosurgery.